Sep 14 2006
Ranbaxy Laboratories Limited (Ranbaxy) has announced that The District Court of The Hague has handed down a decision in Ranbaxy's case against (Pfizer) Warner-Lambert over the cholesterol-lowering drug, atorvastatin, which is marketed by Pfizer as Lipitor(R).
The three-judge panel held that (Pfizer) Warner-Lambert's European Patent 409 281 was invalid in the Netherlands.
However, Ranbaxy's atorvastatin product was ruled to infringe the broadest claims of (Pfizer) Warner-Lambert's European Patent 247 633 in the Netherlands.
Ranbaxy is evaluating this decision and will decide on its course of action shortly.